CMS Finalizes 2027 ESRD PPS Rule, Increasing DefenCath Reimbursement
What happened
CMS finalized the 2027 End-Stage Renal Disease Prospective Payment System (ESRD PPS) final rule on October 28, 2026. The rule established a post-TDAPA Add-on payment of $8.32 per dialysis session for DefenCath® (taurolidine and heparin) for the first quarter of 2027, alongside a new quarterly process for calculating Add-On adjustments. This payment is three to five times higher than the $2.37 rate in effect during the third and fourth quarters of 2026.
From manilatimes.net
Why it matters
The rule changes the reimbursement structure for End-Stage Renal Disease treatment, specifically increasing the payment rate for DefenCath. CorMedix Therapeutics noted that the new Q1 2027 Add-on payment is within its previously guided range, though it stated it has not provided utilization or pricing data to estimate future quarterly adjustments.
From manilatimes.net
Who's involved
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- AscensionSpeculative
Increased reimbursement for DefenCath could increase revenue for providers using the drug.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
CMS
International law firm
- CMS is integrating STEM as a magnet program theme and considering combining it with the International Baccalaureate program.
- Loews Corporation reported its financial results on August 4, 2025, noting that CNA Financial contributed net income to Loews, while Boardwalk Pipelines was also mentioned in the earnings report.